Figure 1.

(A) SLEDAI score of 10 patients during a six month period of treatment with MMF after a significant rise in the level of antibodies to dsDNA. (B) VAS-Pa and (C) VAS-Ph represent the impression of the patient and the treating physician, respectively, of disease activity during the month before the visit to the outpatient clinic. *p<0.05, comparing different time points of evaluation with that at the start of treatment at time 0 (repeated measures analysis of variance with Bonferroni's post-test). Data are presented as mean (SE).